Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
Amgen launched its stand-alone operations in Japan on April 1, marking a departure from its joint venture business with local partner Astellas Pharma as originally planned, with its country chief Steve Sugino vowing that the big biotech aims for global…
To read the full story
Related Article
- Amgen Astellas BioPharma to Become Amgen’s Wholly Owned Subsidiary; Continue Copromotion with Astellas
January 24, 2020
- Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
BUSINESS
- Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
March 31, 2026
- Sumitomo Files Latuda for Pediatric Schizophrenia in Japan
March 31, 2026
- Servier’s Glioma Drug Voranigo Now Available in Japan
March 31, 2026
- Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
- Eisai, MSD File Lenvima-Welireg Combo in Japan for RCC
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…